Skip to main content

Advertisement

SpringerLink
Log in

Dual SGLT1 and SGLT2 inhibitor sotagliflozin achieves FDA approval: landmark or landmine?

  • Comment
  • Published:

From Nature Cardiovascular Research

View current issue Submit your manuscript

The US Food and Drug Administration (FDA) has approved sotagliflozin with a broad heart-failure indication, even in the absence of trial data in patients without diabetes. No one knows what the benefits or risks of inhibiting SGLT1 in the heart might be.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1: Effects of sotaglifozin.

References

  1. Borges-Júnior, F. A. et al. J. Am. Soc. Nephrol. 32, 1616–1629 (2021).

    Article  PubMed  PubMed Central  Google Scholar 

  2. Packer, M. Circulation 146, 1383–1405 (2022).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Chan, L. K. Y., Wang, Y., Ng, E. K. W. & Leung, P. S. Diabetes Obes. Metab. 20, 709–717 (2018).

    Article  CAS  PubMed  Google Scholar 

  4. Turk, E., Zabel, B., Mundlos, S., Dyer, J. & Wright, E. M. Nature 350, 354–356 (1991).

    Article  CAS  PubMed  Google Scholar 

  5. SCORED Investigators. N. Engl. J. Med. 384, 129–139 (2021).

    Article  Google Scholar 

  6. SOLOIST-WHF Trial Investigators. N. Engl. J. Med. 384, 117–128 (2021).

    Article  Google Scholar 

  7. US FDA. INPEFA (sotagliflozin) tablets, for oral use. https://go.nature.com/3CVjPBw (2023).

  8. van Raalte, D. H. et al. Diabetes Care 42, 1921–1929 (2019).

    Article  PubMed  PubMed Central  Google Scholar 

  9. Sayour, A. A. et al. Cardiovasc Diabetol. 19, 159 (2020).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Ramratnam, M. et al. J. Am. Heart Assoc. 3, e000899 (2014).

    Article  PubMed  PubMed Central  Google Scholar 

  11. Connelly, K. A., Zhang, Y., Desjardins, J. F., Thai, K. & Gilbert, R. E. Cardiovasc. Diabetol. 17, 99 (2018).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Ferté, L. et al. Am. J. Physiol. Heart Circ. Physiol. 320, H838–H853 (2021).

    Article  PubMed  PubMed Central  Google Scholar 

  13. Takebayashi, K. & Inukai, T. J. Clin. Med. Res. 9, 745–753 (2017).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Posch, M. G. et al. Diabetes Care 45, 2118–2126 (2022).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Sudo, M. et al. Atherosclerosis 265, 283–291 (2017).

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Baylor Heart and Vascular Institute, Dallas, TX, USA

    Milton Packer

  2. Imperial College, London, UK

    Milton Packer

Authors
  1. Milton Packer
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Milton Packer.

Ethics declarations

Competing interests

In the past three years, M.P. has been a consultant to 89bio, Abbvie, Altimmune, Amgen, Ardelyx, AstraZeneca, Boehringer Ingelheim, Caladrius, Casana, CSL Behring, Cytokinetics, Imara, Lilly, Moderna, Novartis, Pharmacosmos, Reata, Regeneron, Relypsa and Salamandra.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Packer, M. Dual SGLT1 and SGLT2 inhibitor sotagliflozin achieves FDA approval: landmark or landmine?. Nat Cardiovasc Res 2, 705–707 (2023). https://doi.org/10.1038/s44161-023-00306-x

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s44161-023-00306-x

  • Springer Nature Limited

Search

Navigation